Erythropoiesis is a complex multistep process extending from committed erythroid progenitors to mature red cells and involving a talk to talk process with other haematopoietic progenitors. Although some recent advances now make it possible to characterize some components of erythropoiesis, much still remains to be investigated, in particular as regards pathological erythropoiesis and in the haematological conditions characterized by ineffective erythropoiesis. During erythropoiesis, efficient cytoprotective systems are required to limit possible ROS-related toxic effects: these systems play an even more important role in conditions of ineffective erythropoiesis (IE), such as thalassaemias, sickle cell disease and congenital dyserythropoietic anaemias (CDAs), but also in myelodysplastic syndromes (MDS). Blood transfusion therapy or treatments with erythropoiesis stimulating agents (ESAs), such as recombinant EPO, are so far the frontline therapies for anaemia associated with ineffective erythropoiesis (IE). However, both treatments are not without risk, and in some cases they are not effective. Therefore, there is a clinical need for novel agents supporting IE with different mechanism(s) of action from existing ESAs.
The European School of Hematology (ESH) organizes the meeting International Conference on Erythropoiesis Control and Ineffective Erythropoiesis: from Bench to Bedside, which will take place on 2019, March, 15-17, in Budapest, Hungary.
The meeting is structured with the specific aim to be translational “from bench to bedside”, and to involve participants in lively interactive discussions offering a unique opportunity to discuss basic science in a clinical context. The two and half day programme includes 9 sessions that will alternate basic science and clinical practice, with a focus on specific diseases such as CDAs, thalassaemia, SCD, haemolytic anaemias and MDS. Find here the preliminar agenda.